Turrini O.,Institute Paoli Calmettes |
Paye F.,University Paris 06 |
Sauvanet A.,AP HP Hopital Beaujon |
Sa Cunha A.,Maison du Haut Leveque |
And 4 more authors.
European Journal of Surgical Oncology | Year: 2013
Aim: To determine the benefit of surgery for resectable pancreatic adenocarcinomas (PAs) in elderly patients. Methods: From 2004 to 2009, 932 patients with resectable PAs underwent pancreatectomies without neoadjuvant treatment in 37 institutions. The patients were divided into three groups according to age: <70 years (control group; n = 580); 70-79 years (70s group, n = 288), and ≥80 years (80s group; n = 64). Preoperative, intraoperative, postoperative, and histological data were recorded to assess the postoperative course and survival. Results: Preoperative or intraoperative characteristics, and the histological findings were comparable in the three groups. Postoperative mortality and morbidity rates did not differ in the three groups. Adjuvant therapies were more frequently used in younger patients than in elderly patients (p < 0.01). The overall 1-year, 3-year, and 5-year survival rates of control group/70's group/80's group were 82.2%/75.7%/75.7%, 49.9%/41.8%/31%, and 38.7%/33.2%/0%, respectively (p = 0.16). The median survival of the control, 70s, and 80s groups was 24 months, 35.3 months, and 30 months, respectively. Four independent prognostic indicators were identified by multivariate analysis: venous invasion (hazard ratio (HR) = 2.12), arterial invasion (HR = 2.96), positive lymph nodes (HR = 2.25), and adjuvant treatment (HR = 0.65). Conclusions: Fit elderly patients with resectable PAs should not be excluded from surgical resection of PA solely because of their real age. Moreover, elderly patients seem to obtain similar advantages from pancreatectomies than younger patients. © 2012 Elsevier Ltd. All rights reserved.
Addeo P.,University of Strasbourg |
Delpero J.R.,Institute Paoli Calmettes |
Paye F.,University Paris - Sud |
Oussoultzoglou E.,University of Strasbourg |
And 8 more authors.
HPB | Year: 2014
Backgrounds A pancreatic fistula (PF) is the most relevant complication after a pancreaticoduodenectomy (PD). This retrospective multicentric study attempts to elucidate the risk factors and complications of a PF in a large cohort of patients undergoing a PD for ductal adenocarcinoma. Methods Using a survey tool, clinical data of 1325 patients undergoing a PD for ductal adenocarcinoma at 37 institutions, between January 2004 and December 2009, were collected. Peri-operative risk factors associated with PF and its association with morbidity and mortality were assessed. Morbidity and PF were graded according to the ISGPF (International Study group for pancreatic fistula) definition and the Dindo-Clavien classification. Results Overall PF, mortality, morbidity and relaparotomy rates were 14.3%, 3.8%, 54.4% and 11.7%, respectively. PF occurred more frequently after a pancreaticojejunostomy (PJ) compared with a pancreaticogastrostomy (PG) (16.8% vs. 10.4%; P = 0.0012). Independent risk factors for PF by multivariate analysis were absence of pre-operative diabetes (P = 0.0014), PJ reconstruction (P = 0.0035), soft pancreatic parenchyma (P < 0.0001) and low-volume centre (P = 0.0286). Clinically relevant PF (grade B and C) and severe complications (Dindo-Clavien grade IIIB, IV, V) were significantly more frequent after PJ than PG (71.6% vs. 28.3%; P = 0.030 and 24.8% vs. 19.1%; P = 0.015, respectively). Overall mortality and relaparotomy rates were similar after PG and PJ. Conclusions A soft pancreatic parenchyma, the absence of pre-operative diabetes, PJ and low-volume centre are independent risk factors for PF after PD for ductal adenocarcinoma. A significantly higher incidence and clinical severity of PF are associated with PJ. © 2013 International Hepato-Pancreato-Biliary Association.
Boulvain M.,University of Geneva |
Senat M.-V.,University Paris - Sud |
Perrotin F.,Pole de Gynecologie obstetrique |
Winer N.,Hopital Mere enfant |
And 16 more authors.
The Lancet | Year: 2015
Background Macrosomic fetuses are at increased risk of shoulder dystocia. We aimed to compare induction of labour with expectant management for large-for-date fetuses for prevention of shoulder dystocia and other neonatal and maternal morbidity associated with macrosomia. Methods We did this pragmatic, randomised controlled trial between Oct 1, 2002, and Jan 1, 2009, in 19 tertiary-care centres in France, Switzerland, and Belgium. Women with singleton fetuses whose estimated weight exceeded the 95th percentile, were randomly assigned (1:1), via computer-generated permuted-block randomisation (block size of four to eight) to receive induction of labour within 3 days between 37+0 weeks and 38+6 weeks of gestation, or expectant management. Randomisation was stratified by centre. Participants and caregivers were not masked to group assignment. Our primary outcome was a composite of clinically significant shoulder dystocia, fracture of the clavicle, brachial plexus injury, intracranial haemorrhage, or death. We did analyses by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00190320. Findings We randomly assigned 409 women to the induction group and 413 women to the expectant management group, of whom 407 women and 411 women, respectively, were included in the final analysis. Mean birthweight was 3831 g (SD 324) in the induction group and 4118 g (392) in the expectant group. Induction of labour significantly reduced the risk of shoulder dystocia or associated morbidity (n=8) compared with expectant management (n=25; relative risk [RR] 0·32, 95% CI 0·15-0·71; p=0·004). We recorded no brachial plexus injuries, intracranial haemorrhages, or perinatal deaths. The likelihood of spontaneous vaginal delivery was higher in women in the induction group than in those in the expectant management group (RR 1·14, 95% CI 1·01-1·29). Caesarean delivery and neonatal morbidity did not differ significantly between the groups. Interpretation Induction of labour for suspected large-for-date fetuses is associated with a reduced risk of shoulder dystocia and associated morbidity compared with expectant management. Induction of labour does not increase the risk of caesarean delivery and improves the likelihood of spontaneous vaginal delivery. These benefits should be balanced with the effects of early-term induction of labour. Funding Assistance Publique-Hôpitaux de Paris and the University of Geneva. © 2015 Elsevier Ltd.
Schleinitz N.,Aix - Marseille University |
Vely F.,Aix - Marseille University |
Harle J.,Hopital de la Conception |
Vivier E.,Aix - Marseille University |
And 3 more authors.
Immunology | Year: 2010
Summary: Natural killer (NK) cells have been implicated in tumour surveillance and in the early control of several microbial infections. In autoimmune disease their involvement in these processes has been evaluated in animal models, with conflicting results. Both a disease-controlling and a disease-promoting role have been suggested. In human autoimmune disease only a few studies, mainly descriptive, have demonstrated qualitative and quantitative modification of NK cells. These changes were observed on blood- or tissue-infiltrating NK cells. Taken together with our expanding knowledge of the genetical variability of NK cell receptors and NK cell physiology, these findings pave the way for the dissection of the role of NK cells in human autoimmune diseases. NK cells may be directly involved in these diseases through their potential autoreactivity or through their interaction with dendritic cells, macrophages or T lymphocytes, thereby inducing excessive inflammation or favouring the adaptive autoimmune response. Thus, NK cells may be implicated in the onset, the maintenance or the progression of autoimmune diseases. Some reports also suggest the involvement of NK cells in the treatment of human autoimmune disease by biotherapies. All these observations suggest that NK cells are involved in the complex processes of autoimmune diseases. Nevertheless, further careful analysis of NK cells at different steps of these diseases, in different tissues and through combined genetical and functional studies will contribute to a better understanding of their role in autoimmune diseases. This knowledge might allow the development of new therapeutic strategies based on NK cells for the treatment of some autoimmune diseases. © 2010 The Authors. Immunology © 2010 Blackwell Publishing Ltd.
Mouttet A.,Saint Roch private hospital |
Louis M.-L.,Hopital de la Conception |
Sourdet V.,EUROS corporation
Orthopaedics and Traumatology: Surgery and Research | Year: 2011
Introduction: The success of total knee arthroplasty is measured by pain relief, functional recovery, and implant survival duration.The aim of the present study was to evaluate the long-term clinical, functional and radiological results of the posterior cruciate ligament (PCL)-retaining fixed bearing EUROP implant. Hypothesis: The long-term results of EUROP implants are similar to those reported with comparable prostheses. Patients and methods: We performed a prospective, monocentric study of a series of 121 cemented EUROP total knee arthroplasties, implanted between 1994 and 1996 in 117 patients mean age 73. A clinical and radiological evaluation was performed at 10 years of follow-up according to the International Knee Society (IKS) score. Twenty-three patients died, 14 were lost to follow-up, 43 underwent clinical and radiological evaluation and 37 were questioned by telephone. Results: The preoperative IKS knee score was 31 points (0-60) and increased to 88 points (30-98) at final follow-up, IKS function increased from 40 (0-90) to 80 points (25-100). Radiolucencies were observed in 56% of the condyles and 60% of tibial plates. Ninety-three percent of these radiolucent lines were less than 1. mm wide. Three patients underwent revision TKA at 32 months, eight and 11 years respectively. Global implant survival was 99% at five years, 97.8% at 10 years and 95.8% at 12 years. Discussion: The clinical and radiological results of the cruciate-retaining fixed bearing EUROP total knee arthroplasties, with three cases of revision arthroplasty at 12 years of follow-up are satisfactory and comparable to similar implants. Level of evidence: Level IV; prospective study. © 2011 Elsevier Masson SAS.